Mismatch Repair Deficient (dMMR)
1 drugsPredictive biomarker for patient selection in 9 indications
1
Approved Drugs
9
Indications
1
Companies
Mismatch Repair Deficient (dMMR) is a precision-medicine biomarker linked to 1 FDA-approved targeted drug from 1 company, spanning 9 indications including Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Biliary Tract Cancer. Explore the targeted therapies, indications, testing methods, and companies developing Mismatch Repair Deficient (dMMR) drugs below.
Search Mismatch Repair Deficient (dMMR) Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting Mismatch Repair Deficient (dMMR)
| Drug | Company | Therapeutic Area |
|---|---|---|
| IMFINZI | AstraZeneca | Oncology |
Mismatch Repair Deficient (dMMR) Indications
Non-Small Cell Lung Cancer Small Cell Lung Cancer Biliary Tract Cancer Hepatocellular Carcinoma Endometrial Cancer Non-Muscle-Invasive Bladder Cancer Muscle Invasive Bladder Cancer Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma